Compare PLBY & CNTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLBY | CNTN |
|---|---|---|
| Founded | 1953 | 2017 |
| Country | United States | United States |
| Employees | N/A | 12 |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 204.4M | 185.3M |
| IPO Year | 2020 | 2022 |
| Metric | PLBY | CNTN |
|---|---|---|
| Price | $1.38 | $3.06 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 461.0K |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.50 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $120,928,000.00 | N/A |
| Revenue This Year | $9.17 | N/A |
| Revenue Next Year | $7.10 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.13 | N/A |
| 52 Week Low | $1.19 | $2.89 |
| 52 Week High | $2.75 | $5.27 |
| Indicator | PLBY | CNTN |
|---|---|---|
| Relative Strength Index (RSI) | 41.76 | 42.20 |
| Support Level | $1.22 | $3.04 |
| Resistance Level | $1.92 | $3.82 |
| Average True Range (ATR) | 0.10 | 0.27 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 26.62 | 5.83 |
Playboy Inc, formerly PLBY Group Inc connects consumers around the world with products, services, and experiences to help them look good, feel good, and have fun. PLBY Group serves consumers in four categories: Style and Apparel, Digital Entertainment and Lifestyle, Sexual Wellness, and Beauty and Grooming. It operates through three segments Direct-to-Consumer, Licensing, and Digital Subscriptions and Content. It generates revenue through the sales of products and content services to consumers.
Canton Strategic Holdings Inc is engaged in activities related to Canton Network, including the use of Canton Coin, to support blockchain-based infrastructure and the digitization of financial market processes. The company also operates a validator node on the Canton Network to facilitate transaction validation and network operations. It also operates a clinical-stage biotech research and development arm. Its flagship clinical asset, GV104, is being developed for a specific indication for respiratory and/or nervous system depression in military personnel and chemical incident responders. The expanded pipeline includes other indications for GV104 and GV023, an approach to autoimmune diseases as well as an early-stage multispecific biologic platform.